FWD - HHV-6

[Guest guest]

INFECTS almost all chidren by 2 & lasts lifelong. Has been associated

with some neurological disorders, including encephalitis and seizures.

Perhaps plays a role in CFIDS.

The recently discovered human herpesvirus-6 (HHV-6) is being associated

with an increasing number of conditions in which there is evidence of

immunologic dysfunction. A number of widely available antiviral agents

have shown little or no activity against the virus. We found that

Kutapressin (KU), a drug that has been available to practicing

physicians for over 50 years, has potent, previously unexpected

antiviral effects. Cells known to allow replication of HHV-6 were

infected with the virus, under various conditions. Either pretreatment

of the cells prior to infection or treatment shortly after infection,

inhibited viral replication by & gt; 90%. Indirect evidence suggests that

KU may inhibit viral attachment to cellular receptors, and inhibit

intracellular maturation of the virus. Given these in vitro findings,

and the low frequency of toxicity reported with the use of KU, clinical

trials of this drug in patients with evidence of reactivated HHV-6

infection would seem to be warranted. PMID: 7893985, UI: 95201212

Ampligen inhibits human herpesvirus-6 in vitro.- the drug was then

later tested on people

with CFIDS/CFS, and also on people with AIDS-related fatigue. The

results have been very promising.

Dosages can be found in the studies. The company that makes the drug is

called HemispheRx. The second most

effective drug studied so far in these cases is an old drug once used

commonly to treat cystic acne,

called Kutapressin. It is a peptide based porcine liver derivative that

must be injected itramuscularly.

It has broad anti-infalmmatory actions, but the mechanism of action is

unknown. There is some speculation

that HHV-6 is related to or a variant of the African Swine Fever Virus,

and that there is some

immunomodulatory property to Kutapressin that is, as yet, unknown.

Studies using Kutapressin to treat

CFIDS/CFS and to treat AIDS-related symptoms have also been promising.

In those studies, Kutapressin was

given at fairly high doses: 2cc intramuscularly, daily for one to three

months, then biweekly for the

duration of the study. (See various reports by Neenya Ostrom.)

Currently, in people with AIDS on hormone

replacement therapy, Kutapressin is often used as part of a regimen to

control acne. There are reports of

immunological benefits as well. In these cases, Kutapressin is taken in

2cc intramuscular injections every

10-14 days, concurrent with their hormone injections. Kutapressin is

manufactured by SchwarzPharma, and is

available by prescription in the U.S.

--

via Neil S.